Hims & Hers Health Expands into Europe with Acquisition of Digital Health Platform Zava
Telehealth provider Hims & Hers Health announced Tuesday that it will acquire Zava, a European digital health platform, marking a significant step in the company’s global expansion strategy.
The acquisition is expected to broaden Hims & Hers’ presence in the UK and officially launch its services in Germany, France, and Ireland.
The move is part of Hims & Hers’ larger effort to bring its personalized, direct-to-consumer healthcare model to international markets. With Zava’s 1.3 million active customers and a reported 2.3 million medical consultations completed last year, the acquisition could increase Hims’ user base by over 50%, adding to its existing 2.4 million subscribers.
“This acquisition is expected to accelerate Hims & Hers’ vision to deliver the same seamless, personalized care experience it has successfully built in the US to millions more people globally,” the company said in a press release.
The deal is anticipated to close in the second half of 2025 and will be funded entirely through Hims & Hers’ existing cash reserves. Specific financial terms were not disclosed but are expected to be detailed in the company’s second-quarter financial report.
Initially, Zava will maintain its existing branding, with a full rebrand to Hims & Hers expected in the months following the acquisition. Zava CEO David Meinertz will become General Manager of the company’s international business division.
CEO Andrew Dudum emphasized that the European market presents a strong opportunity due to more favorable pharmaceutical pricing and growing demand for accessible, tech-enabled healthcare solutions.
“We’re excited to take this moment to really accelerate both the European expansion and use this platform as an accelerant as we move into more markets,” Dudum told CNBC.
Hims & Hers shares rose more than 6% following the announcement, climbing to $60.64. The stock currently holds a top position on the IBD 50 list of growth stocks and carries a perfect IBD Digital Composite Rating of 99. It also has a high Relative Strength Rating of 98, indicating strong price performance over the past 12 months.
The expansion comes at a dynamic time for the company. Hims recently began offering compounded versions of popular weight-loss drugs, such as Wegovy, amid shortages. Although new US regulations now limit the large-scale production of these medications, Hims has since signed an agreement with drugmaker Novo Nordisk to help patients access the branded version.
In Europe, the acquisition positions Hims to meet high demand for weight management services and other telehealth offerings. Meinertz noted that many patients face barriers to treatment through public healthcare systems, creating an opportunity for platforms like Zava.
While some companies are scaling back growth plans due to economic uncertainty, Hims & Hers is taking a more aggressive approach. Dudum said that personalized, affordable care — particularly in weight management, dermatology, and sexual health — is central to the company’s future.
Investor’s Business Daily, CNBC, Reuters, and the Financial Times.
